Active

Insilico Medicine

General contacts
Investor type

CVC / VC

Founded

2014

AUM

-

Location

Hong Kong, Hong Kong, Hong Kong

Investment Ticket

$10-50 m

Investment Stage

Series A

Region of investment

Asia
Investor profile last updated: 31 August, 2026

Profile

Insilico Medicine is an AI drug developer headquartered in Hong Kong and publicly listed. The firm is a leader in the 'AI for sciences' (AI4S) field, leveraging artificial intelligence to develop new pharmaceuticals and life sciences applications. Insilico's team includes experts in AI, drug discovery, and precision medicine, and is known for its focus on transformative technologies in the life sciences sector. Insilico stands out for its innovative applications of AI in scientific research and development, and for its deep collaboration with leading investment and development partners in China and Hong Kong.

Insilico Medicine invests in the biopharmaceutical and life sciences sectors, including AI-driven drug discovery, precision medicine, and novel drug modalities. The firm is initiating a $150.2 million Exponential Technology Fund in partnership with major investors like Value Partners Group and the Shanghai Pudong Development Group to target the life sciences value chain. Its stages of investment include Series A and beyond, focusing on growth opportunities in China and globally. The planned fund is a showcase of their commitment to transformative life sciences sectors.

Notable investments of Insilico Medicine include its own AI-driven drug discovery platforms and spin-offs from its incubated projects. The firm has been involved in pioneering development in AI laboratories, precision medicine platforms, and life sciences technologies. Through its strategic partnerships, Insilico Medicine continues to deepen its influence in both the AI and life sciences sectors.

Industry

HealthTech Life Sciences MedTech AI Pharmaceuticals Healthcare Services Biotechnology

Insilico Medicine Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region 		Size AUM Launch date
Insilico Medicine Exponential Technology Fund
Venture Capital (VC)
Corporate VC (CVC)
Biotechnology
Pharmaceuticals
AI
MedTech
Life Sciences
Series A
Asia
$10-50 m
$150.2 M
August 2026

Contacts

Name
Title
Email
Social Networks
avatar
Ricardo Gaminha Pacheco, MD MBA MPH Longevity Biotechnology Strategic Partnering, BD & L Senior Director
Longevity Biotechnology Strategic Partnering, BD & L Senior Director
-
LinkedIn
Upgrade to see contacts
avatar
rlPjwnkyoIDLTQes rlPjwnkyoIDLTQes
rlPjwnkyoIDLTQes
[email protected]
linkedin twitter
avatar
rlPjwnkyoIDLTQes rlPjwnkyoIDLTQes
rlPjwnkyoIDLTQes
[email protected]
linkedin twitter
avatar
rlPjwnkyoIDLTQes rlPjwnkyoIDLTQes
rlPjwnkyoIDLTQes
[email protected]
linkedin twitter
avatar
rlPjwnkyoIDLTQes rlPjwnkyoIDLTQes
rlPjwnkyoIDLTQes
[email protected]
linkedin twitter
Investment-team contacts for Insilico Medicine — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Insilico Medicine

Insilico Medicine is a venture capital firm that also operates as a corporate VC (CVC). It backs companies at Series A, writing tickets of $10-50 m.
Insilico Medicine is located in Hong Kong, Hong Kong, Hong Kong.
Insilico Medicine was founded in 2014.
Insilico Medicine invests in companies and startups in HealthTech, Life Sciences, MedTech, AI, Pharmaceuticals, Healthcare Services, Biotechnology.
Insilico Medicine invests in companies and startups in Asia.
Insilico Medicine invests in companies and startups at Series A.
Insilico Medicine usually invests $10-50 m on average.
Insilico Medicine last fund was created/launched in 2026-08-25
Insilico Medicine can be reached through its website insilico.com, its LinkedIn page and its X account. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Insilico Medicine — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Insilico Medicine directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 31 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.